Devanish N. Kamtam MBBS, MS , Joseph B. Shrager MD , Irmina A. Elliott MD , Henry H. Guo MD, PhD , Brandon A. Guenthart MD , Douglas Z. Liou MD , Natalie S. Lui MD , Leah M. Backhus MD , Mark F. Berry MD
{"title":"Utility of PET for Nodal Staging in Subsolid Clinical Stage IA (T1 N0) Lung Adenocarcinoma","authors":"Devanish N. Kamtam MBBS, MS , Joseph B. Shrager MD , Irmina A. Elliott MD , Henry H. Guo MD, PhD , Brandon A. Guenthart MD , Douglas Z. Liou MD , Natalie S. Lui MD , Leah M. Backhus MD , Mark F. Berry MD","doi":"10.1016/j.atssr.2024.07.007","DOIUrl":"10.1016/j.atssr.2024.07.007","url":null,"abstract":"<div><h3>Background</h3><div>Positron emission tomography (PET) is the standard of care for non-small cell lung cancer (NSCLC) clinical staging, but it may have limited utility in evaluating subsolid lung adenocarcinomas that can have relatively indolent behavior without hypermetabolic activity.</div></div><div><h3>Methods</h3><div>The sensitivity and specificity of PET for determining pathologic lymph node status and disease-free survival were assessed in patients operated on for cT1 N0 subsolid lung adenocarcinoma from January 2006 to June 2022 (at Stanford University School of Medicine, Stanford, CA). Patients with clinical or pathologic tumor size >30 mm, hilar or mediastinal lymph node size >1cm, and purely solid tumors were excluded.</div></div><div><h3>Results</h3><div>PET was available in 498 of 534 (93.2%) patients and more often was used in older patients with larger and more solid tumors. The overall pathologic lymph node–positive rate was 8.4% (45 of 534). PET specificity was 95.1%, but sensitivity was only 20.0%. A tumor diameter of 18.5 mm and a solid component percentage of 62.5% had the maximum predictive accuracy for pathologic lymph node positivity, with a 0% and 1.5% rate of pathologic and PET lymph node positivity, respectively, for tumors with values lower than those thresholds. There was no significant difference in 5-year disease-free survival between individuals who did and did not undergo PET scanning (76.6% vs 96.8%; <em>P</em> = .07). Conversely, 134 (26.9%) patients who underwent PET scanning had 171 incidentally detected hypermetabolic lesions unrelated to lung cancer, with only 13 of 134 (9.7%) patients identified as having non-NSCLC premalignant or malignant conditions requiring further therapy.</div></div><div><h3>Conclusions</h3><div>PET scan use for subsolid lung adenocarcinoma has high specificity but limited sensitivity for predicting pathologic lymph node positivity. PET also has no association with disease-free survival and often detects clinically unimportant findings rather than changing lung cancer management, particularly for patients with smaller and less solid tumors.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 118-122"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer L. Keen MD , Pranav Modi MBBS , Maria M. Crespo MD , Christian Bermudez MD , Andrew Courtwright MD, PhD
{"title":"Survival After Extracorporeal Membrane Oxygenation Bridge to Lung Retransplantation","authors":"Jennifer L. Keen MD , Pranav Modi MBBS , Maria M. Crespo MD , Christian Bermudez MD , Andrew Courtwright MD, PhD","doi":"10.1016/j.atssr.2024.09.018","DOIUrl":"10.1016/j.atssr.2024.09.018","url":null,"abstract":"<div><h3>Background</h3><div>Extracorporeal membrane oxygenation (ECMO) is increasingly used as a bridge to lung transplantation. Despite success in select populations, candidates requiring ECMO bridge to retransplantation have historically had poor 1-year survival. This study aimed to examine the characteristics of the recipient, donor, and transplant procedure type to guide selection of candidates for ECMO bridge to retransplantation.</div></div><div><h3>Methods</h3><div>This was a retrospective cohort study of all US adult lung retransplant recipients between May 5, 2005, and December 31, 2022. We evaluated 1-year survival of ECMO-bridged retransplant patients, stratified by time from initial transplant, procedure type (single or bilateral retransplant), and ECMO era (2005-2017 vs 2018-2022).</div></div><div><h3>Results</h3><div>In this national cohort, 111 of 1296 (8.6%) retransplant recipients underwent ECMO bridge. One-year survival was worse for ECMO bridge retransplant recipients (52.2% vs 74.0%; <em>P</em> < .001) and has worsened in the contemporary era (2018-2022) of ECMO bridge to retransplantation compared with prior years (<em>P</em> = .03). Time from initial transplantation and use of bilateral retransplant after an initial bilateral transplant were most strongly associated with improved 1-year survival of ECMO-bridged retransplant recipients. Of bilateral recipients bridged to bilateral transplant more than 1 year after primary transplantation, survival was 65.9% in ECMO-bridged patients as opposed to 77.2% in nonbridged patients.</div></div><div><h3>Conclusions</h3><div>Careful selection of candidates and surgical procedure type remains essential in determining candidacy for ECMO bridge to retransplantation.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 150-155"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren C. Ryan BS , Sania Choudhary , Ntemena Kapula MAS , Augustine Kang PhD , Laura G. Shula PA-C , Irmina A. Elliott MD , Brandon A. Guenthart MD , Douglas Z. Liou MD , Leah M. Backhus MD, MPH , Mark F. Berry MD , Joseph B. Shrager MD , Natalie S. Lui MD
{"title":"Community Awareness of Lung Cancer Screening: A Cross-Sectional Survey","authors":"Lauren C. Ryan BS , Sania Choudhary , Ntemena Kapula MAS , Augustine Kang PhD , Laura G. Shula PA-C , Irmina A. Elliott MD , Brandon A. Guenthart MD , Douglas Z. Liou MD , Leah M. Backhus MD, MPH , Mark F. Berry MD , Joseph B. Shrager MD , Natalie S. Lui MD","doi":"10.1016/j.atssr.2024.08.010","DOIUrl":"10.1016/j.atssr.2024.08.010","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer remains the leading cause of cancer mortality in the United States, but only 4.5% of eligible people undergo recommended screening. We hypothesize that low community awareness remains a barrier to lung cancer screening.</div></div><div><h3>Methods</h3><div>A cross-sectional survey was conducted in a convenience sample of attendees at our institution’s community health fair. Survey topics included demographics, smoking history, cancer history, lung cancer screening knowledge, and perceptions of screening risks and benefits.</div></div><div><h3>Results</h3><div>Of 214 survey participants, 139 (65%) were women, and there were 98 (46%) Asian and 86 (40%) White participants. Almost a third of the sample had worked in health care, and just more than a half had completed some graduate school. There were only 6 (2.8%) current smokers and 28 (13%) former smokers. Most participants (71%) did not know there was a way to screen for lung cancer. Most participants (66%) knew that cigarette smoking was the risk factor considered for lung cancer screening, but very few knew the screening criteria. More than 75% of participants chose “strongly agree” or “agree” that several benefits of lung cancer screening are important to consider, but only 50.0% to 66.3% for several risks. Most participants (71%) responded that they are “very likely” or “likely” to undergo screening if eligible.</div></div><div><h3>Conclusions</h3><div>In a survey study at a community health fair, community awareness of lung cancer screening was very low, but most participants said they would be willing to be screened if eligible. Community education is critical in increasing our lung cancer screening rates.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 113-117"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Ross Procedure in Active Infective Endocarditis: A Comparison With Conventional Prostheses","authors":"Hiromu Kehara MD, PhD , Mohammed Kashem MD, PhD , Huaqing Zhao PhD , Sebastian A. Iturra MD , Suyog A. Mokashi MD , Ravishankar Raman MD , Roh Yanagida MD, PhD , Kewal Krishan MD , Norihisa Shigemura MD, PhD , Yoshiya Toyoda MD, PhD","doi":"10.1016/j.atssr.2024.08.011","DOIUrl":"10.1016/j.atssr.2024.08.011","url":null,"abstract":"<div><h3>Background</h3><div>The Ross procedure can be an ideal option in infective endocarditis (IE) due to greater resistance to infection. However, limited literature has highlighted the comparison with conventional prostheses in this setting.</div></div><div><h3>Methods</h3><div>Between February 2013 and September 2022, 25 patients (median age, 50 years) underwent a Ross procedure for IE (Ross group). The results were compared with those after other aortic valve procedures (aortic valve replacement and aortic root replacement) for IE (n = 37, other group.</div></div><div><h3>Results</h3><div>The patients in the Ross group included more intravenous drug users and had more prosthetic valve endocarditis and annular abscess formation compared with the other group. Although cardiopulmonary bypass time and aortic cross-clamp time were significantly longer (<em>P</em> < .001 and <em>P</em> = .003, respectively) and the blood requirements were significantly higher (<em>P</em> = .001) in the Ross group, most postoperative short-term outcomes were equivalent between the 2 groups. During follow-up, 1 patient (4%) required reoperation in the Ross group, whereas 6 patients (16%) required reoperation in the other group. Freedom from composite events was significantly better in the Ross group (<em>P</em> = .04). Multivariable analysis found the Ross procedure, compared with other procedures, was a significant independent protective factor for composite end points (<em>P</em> = .03).</div></div><div><h3>Conclusions</h3><div>For IE, despite surgical complexity, the Ross procedure yielded short-term outcomes similar to other procedures. In the midterm, the Ross procedure provides a lower reoperation rate, resulting in significantly fewer composite events. The Ross procedure appears to be a better option for patients with IE, but long-term follow-up is necessary.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 47-51"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Successful Tricuspidization of Bicuspid Aortic Valve Complicated by Anomalous Coronary Artery","authors":"Kazuki Hisatomi MD, PhD , Kiyoyuki Eishi MD, PhD , Ichiro Matsumaru MD, PhD , Kikuko Obase MD, PhD , Takashi Miura MD, PhD","doi":"10.1016/j.atssr.2024.07.018","DOIUrl":"10.1016/j.atssr.2024.07.018","url":null,"abstract":"<div><div>Repair of an asymmetrical bicuspid aortic valve remains a complicated endeavor. Here, we present a successful aortic valve repair for severe aortic regurgitation associated with such a bicuspid aortic valve, further complicated by an anomalous coronary artery. The nonsevered dilated aortic root was reshaped by the sleeve procedure with a Valsalva graft, and the raphe was lifted up to reconstruct the functional commissure, which enabled tricuspidization. Correcting the anomalous aortic origin of the right coronary artery, which posed a risk of myocardial ischemia because of its interarterial course, was achieved by translocating it to the right sinus of Valsalva.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 57-59"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Understanding Oxygen Delivery","authors":"Rawn Salenger MD","doi":"10.1016/j.atssr.2024.08.006","DOIUrl":"10.1016/j.atssr.2024.08.006","url":null,"abstract":"","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Page 270"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aravind Krishnan MD , Elbert Heng MD , Chawannuch Ruaengsri MD , Amit Banga MD , Brandon A. Guenthart MD , Y. Joseph Woo MD , John Ward MacArthur MD
{"title":"Use of Ex-Vivo Lung Perfusion for Planned Left Single-Lung Transplant","authors":"Aravind Krishnan MD , Elbert Heng MD , Chawannuch Ruaengsri MD , Amit Banga MD , Brandon A. Guenthart MD , Y. Joseph Woo MD , John Ward MacArthur MD","doi":"10.1016/j.atssr.2024.07.025","DOIUrl":"10.1016/j.atssr.2024.07.025","url":null,"abstract":"<div><div>The donor shortage in lung transplantation is further exacerbated by the highest organ turn-down rate among all solid organ transplants. Here we present a case of planned single-lung ex-vivo lung perfusion that enabled the use of a single lung for transplantation, that otherwise may have gone unallocated. Creative management of the donor trachea enabled use of both the left and right lungs for separate recipients. Techniques like this may inspire confidence in expansion in use of ex-vivo lung perfusion and a commensurate increase in donor organ utilization for lung transplantation.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 247-249"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennie Hocking MPAS , John B. Eisenga MD , Austin Kluis MD , Kyle A. McCullough MD , Ghadi Moubarak MD , J. Michael DiMaio MD , William Ryan MD
{"title":"Predictors of Survival After Triple Valve Surgery: A Single Center Analysis","authors":"Jennie Hocking MPAS , John B. Eisenga MD , Austin Kluis MD , Kyle A. McCullough MD , Ghadi Moubarak MD , J. Michael DiMaio MD , William Ryan MD","doi":"10.1016/j.atssr.2024.07.021","DOIUrl":"10.1016/j.atssr.2024.07.021","url":null,"abstract":"<div><h3>Background</h3><div>Triple valve surgery is a complex operation with high perioperative mortality. Limited data exist regarding the predictors of success associated with this surgery. We report our experience.</div></div><div><h3>Methods</h3><div>A total of 211 sequential patients underwent triple valve surgery at 1 hospital from November 2007 through July 2022. Baseline characteristics, operative details, and mortality outcomes were reviewed.</div></div><div><h3>Results</h3><div>Eighty-two (38.9%) were redo operations and 68 (32.2%) were urgent. Commonly, aortic (n = 194; 91.4%) and mitral (n = 140; 66.4%) valves were replaced, and the tricuspid valve (n = 189; 89.6%) repaired. Concomitant procedures were done in 28% of patients. Thirty-day mortality was 21 of 211 (9.95%). Kaplan-Meyer survival at 1 and 7 years was 86.0% (interquartile range, 79%-93%) and 64.0% (interquartile range, 55%-74%), respectively. On multivariate regression, end-stage renal disease (hazard ratio, 4.16; <em>P</em> = .003) was associated with mortality, and mitral valve replacement (hazard ratio, 0.44; <em>P</em> = .009) was associated with improved long-term survival.</div></div><div><h3>Conclusions</h3><div>Despite the high number of redo and concomitant procedures, we report a 30-day mortality rate under 10% and an 86% 1-year survival. In our series, mitral valve replacement conferred a long-term survival benefit.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 25-30"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emmanuel Lansac MD, PhD , Kevin M. Veen MD, PhD , Andria Joseph MSc , Paula Blancarte Jaber MD, MSc , Frieda Sossi MSc , Zofia Das-Gupta PhD , Suleman Aktaa MD, PhD , J. Rafael Sádaba MD, PhD , Vinod H. Thourani MD , Gry Dahle MD, PhD , Wilson Y. Szeto MD , Faisal Bakaeen MD , Elena Aikawa MD, PhD , Frederick J. Schoen MD, PhD , Evaldas Girdauskas MD , Aubrey Almeida MBBS , Andreas Zuckermann MD , Bart Meuris MD, PhD , John Stott , Jolanda Kluin MD, PhD , Johanna J.M. Takkenberg MD, PhD
{"title":"The First International Consortium for Health Outcomes Measurement (ICHOM) Standard Dataset for Reporting Outcomes in Heart Valve Disease: Moving From Device- to Patient-Centered Outcomes","authors":"Emmanuel Lansac MD, PhD , Kevin M. Veen MD, PhD , Andria Joseph MSc , Paula Blancarte Jaber MD, MSc , Frieda Sossi MSc , Zofia Das-Gupta PhD , Suleman Aktaa MD, PhD , J. Rafael Sádaba MD, PhD , Vinod H. Thourani MD , Gry Dahle MD, PhD , Wilson Y. Szeto MD , Faisal Bakaeen MD , Elena Aikawa MD, PhD , Frederick J. Schoen MD, PhD , Evaldas Girdauskas MD , Aubrey Almeida MBBS , Andreas Zuckermann MD , Bart Meuris MD, PhD , John Stott , Jolanda Kluin MD, PhD , Johanna J.M. Takkenberg MD, PhD","doi":"10.1016/j.atssr.2024.05.005","DOIUrl":"10.1016/j.atssr.2024.05.005","url":null,"abstract":"<div><h3>Background</h3><div>Globally significant variation in treatment and course of heart valve disease (HVD) exists, and outcome measurement is procedure focused instead of patient focused. This article describes the development of a patient-related (International Consortium for Health Outcomes Measurement) standard set of outcomes and case mix to be measured in patients with HVD.</div></div><div><h3>Methods</h3><div>A multisociety working group was formed that included patient representatives and representatives from scientific cardiology and cardiothoracic surgery societies that publish current guidelines for HVD. The standard set was developed to monitor the patient’s journey from diagnosis to treatment with either a surgical or transcatheter procedure. Candidate clinical and patient-reported outcome measures (PROMs) and case mix were identified through benchmark analyses and systematic reviews. Using an online modified Delphi process, the working group voted on final outcomes/case mix and corresponding definition.</div></div><div><h3>Results</h3><div>Patients with aortic/mitral/tricuspid valve disease or root/ascending aorta >40 mm were included in the standard set. Patients entered the dataset when the diagnosis of HVD was established, allowing outcome measurement in the preprocedural, periprocedural, and postprocedural phases of patients’ lives. The working group defined 5 outcome domains: vital status, patient-reported outcomes, progression of disease, cardiac function and durability, and complications of treatment. Subsequently, 16 outcome measures, including 2 patient-reported outcomes, were selected to be tracked in patients with HVD. Case-mix variables included demographic factors, demographic variables, echocardiographic variables, heart catheterization variables, and specific details on aortic/mitral/tricuspid valves and their specific interventions.</div></div><div><h3>Conclusions</h3><div>Through a unique collaborative effort between patients and cardiology and cardiothoracic surgery societies, a standard set of measures for HVD was developed. This dataset focuses on outcome measurement regardless of treatment, moving from procedure- to patient-centered outcomes. Implementation of this dataset will facilitate global standardization of outcome measurement, allow meaningful comparison between health care systems and evaluation of clinical practice guidelines, and eventually improve patient care for those experiencing HVD worldwide.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 71-85"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ross Procedure With a Symmetric Quadricuspid Pulmonary Autograft","authors":"Scott DeRoo MD , Christopher Burke MD","doi":"10.1016/j.atssr.2024.07.029","DOIUrl":"10.1016/j.atssr.2024.07.029","url":null,"abstract":"<div><div>Quadricuspid pulmonary valve is an uncommon congenital anomaly. Little information is available about use of nonstandard pulmonary valves for the Ross procedure. Here we report the use of a symmetric quadricuspid pulmonary valve as a Ross autograft, including technical implantation details, and demonstrate an acceptable 1-year outcome.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 60-63"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}